Fondaparinux for superficial vein thrombosis

In this trial of 3002 patients with acute symptomatic superficial vein thrombosis (without DVT/PE), they were randomized to fondaparinux 2.5mg a day or placebo for 45 days. The intervention group had significantly fewer events (death, PE/DVT, or recurrence) than the placebo group (1% vs 6%) with major bleeding about 1% in each group. Fondaparinux should be considered for patients with acute symptomatic superficial venous thrombosis (abstract)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment